Purpose of review Peyronie's disease
is a relatively common condition affecting men with estimates of current prevalent rates ranging from 1 to 4%. However, it has no clear management protocols, primarily due to a lack of high quality evidence in support of treatment options. This article aims to review the recent published literature on management strategies for Peyronie's disease
Intralesional interferon therapy has shown to result in significant improvement in Peyronie's disease
plaques and curvature. Intralesional verapamil and extracorporeal shock wave therapy may help retard the progression of disease. Acellular, extracellular matrix-based grafts provide durable long-term satisfactory results in men requiring complex reconstruction.
Further clinical trails are warranted to evaluate the role of oral systemic therapies for early Peyronie's disease
. Injection therapy
, primarily with interferon, seems to be the most promising treatment for early stage Peyronie's disease
. For men with established plaques, surgery using either plication or grafts forms the mainstay. There is an increasing trend to use autologous graft material that is commercially available and avoids donor site complications from autologous tissue.